First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion

Stock Information for Longeveron Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Longeveron Inc.

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference
Bone Biologics Announces Closing of $5.0 Million Public Offering
Bone Biologics Announces Pricing of $5.0 Million Public Offering
Bone Biologics Files Patent Application for Bone Regeneration Technology
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
Bone Biologics Announces 1-for-6 Reverse Stock Split
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.